Premium
Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial
Author(s) -
Minagawa Tomonori,
Oguchi Tomohiko,
Saitou Tetsuichi,
Fukazawa Ayumu,
Hashida Iwao,
Koiwai Keiichiro,
Iijima Kazuyoshi,
Kato Haruaki,
Ogawa Teruyuki,
Ishizuka Osamu
Publication year - 2021
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14487
Subject(s) - medicine , tadalafil , brachytherapy , international prostate symptom score , prostate cancer , urology , adverse effect , tamsulosin , lower urinary tract symptoms , clinical endpoint , prostate brachytherapy , randomized controlled trial , prostate , erectile dysfunction , cancer , radiation therapy , hyperplasia
Objective To study the efficacy of phosphodiesterase‐5 inhibitor tadalafil in attenuating adverse events after low‐dose‐rate brachytherapy for prostate cancer. Methods This was a randomized open‐label trial, conducted at two institutions. Prostate cancer patients undergoing low‐dose‐rate brachytherapy were randomly assigned to receive tadalafil (study group) or tamsulosin (control group). The primary endpoint was International Prostate Symptom Score for subjective evaluation of lower urinary tract symptoms. Uroflowmetry, postvoid residual urine volume, and Sexual Health Inventory for Men score were the secondary endpoints. Each clinical variable was evaluated during a follow‐up period of 1 year after low‐dose‐rate brachytherapy. Results A total of 107 patients were enrolled in this study, with a final total of 96 patients analyzed. The mean total International Prostate Symptom Score changes at 1, 3, 6, 9, and 12 months after low‐dose‐rate brachytherapy were +7.4, +7.1, +4.7, +1.5, and +0.8, respectively, in the tamsulosin group, and +8.5, +9.2, +6.4, +4.1, and +1.6, respectively, in the tadalafil group. There were no statistically significant differences in International Prostate Symptom Score with the exception of the score at 9‐month follow‐up. Moreover, there were no statistically significant differences in any of the uroflowmetry or postvoid residual urine volume findings. The Sexual Health Inventory for Men score in the tadalafil group was significantly higher than that in the tamsulosin group at 6, 9, and 12 months after low‐dose‐rate brachytherapy. Conclusions Tadalafil could be an effective option for the management of lower urinary tract symptoms after low‐dose‐rate brachytherapy.